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OBJECTIVES:Deaths due to opioid over-dosage have increased over the last decade
and now represent the most frequent cause of death due to poisoning. This study
examined the temporal association between prescription opioid use between 2000
and 2005 and the number of opioid-poisoning deaths. METHODS: The number of
annual opioid-poisoning deaths from 2000-05was obtained from theNational Vital
Statistics System multiple causes of injury mortality files (Warner 2009). Data for
annual prescription opioid use was obtained from a published study that reported
opioid use from 2.7 to 3.8 million enrollees annually using the HealthCore Blue
Cross and Blue Shield national commercial insurance plans (Sullivan 2008). The
temporal relationship between several opioid use measures and the number of
opioid deaths/year was studied using ordinary least square regression. RESULTS:
The cumulative opioid dose among all recipients increased from204mgsmorphine
equivalents/enrollee/year to 371 mgs and among opioid users with a non-cancer
pain diagnosis from 2473mgs to 3406mgs. During this period, the number of yearly
opioid deaths increased from4,419 in 2000 to 10,947 in 2005. Therewas a significant
linear relationship between the cumulative yearly opioid dose/enrollee/year and
the number of opioid-poisoning deaths (p0.0001, R20.98). A significant positive
linear relationshipwas also observed between thenumber of annual opioid-related
deaths and opioid use measures of cumulative yearly opioid dose (p0.0001,
R20.98), opioid dose/prescription (p0.0053, R20.88) and mean days-supplied of
opioids/year (p0.0001, R20.99). CONCLUSIONS: A strong linear relationship be-
tween opioid-poisoning deaths and several prescription opioid use measures sug-
gests that the acquisition of prescribed opioids through legal channels is associated
with the national opioidmortality rate. This calls for added vigilance on the part of
prescribers and policy makers to ensure safe use of opioid analgesics. Further
research is warranted to confirm these correlations.
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OBJECTIVES: Essential Medicine policy is a important component of China’s un-
dergoing healthcare reform,while the essential medicine list(the “EML”) is the core
of the essential medicine policy. On August 18, 2009, China issued national essen-
tial medicine list (the “NEML”,1st edition) with 205 western medicines and 102
traditional Chinese medicines(the “TCM”) in it, and each province can add further
medicines to the NEML to form its own provincial essential medicine list (the
“PEML”) under specific circumstances. This paper aims at supporting for the next
round adjustment of the NEML through analyzing the situation of addition to the
NEML by each province. METHODS: To study the addition to the NEML by each
province, this paper analyzes the number of medicines added to NEML in all 31
provincial regions in china during the period of August 18, 2009 to January 1, 2011
through searching the official websites, spot investigation and interview the
officials. RESULTS: (1) So far there are 18 provincial regions having added further
medicines to the EML; (2) Regardless of folk medicine, the average number of es-
sential medicines added in each province is 187,among which western medicines
added 115 while the TCM added 72. (3) Shanghai added the largest number of
medicines to its PEML, i.e. 381,while Qinghai Province added the smallest number
of 60. (4)Some autonomous regions added folk medicines to the PEML according to
the local conditions. CONCLUSIONS: (1) it’s necessary for China to adjust the
NEML(1st edition) reasonably based on the number ofmedicines added to the PEML
and drug using characteristics in each province;(2)The more developed the econ-
omy, the more the further essential medicines added, which leads to unfair and
lower the accessiblity to essential medicines in poor areas, thus the government
should increase investment in poor areas.
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OBJECTIVES: To assess the influence of a quality improvement initiative on the
rate of potentially inappropriate medications (PIMs) in primary care elderly
patients.METHODS: A 3-year, multi-phase prospective demonstration project tar-
geting all 303 general practitioners (GPs) in the Local Health Authority (LHU) of
Parma, Italy, was established in 2007. A panel of Parma LHUexperts developed a list
of PIMs deemed to be always avoided for older patients according to the literature.
The quality improvement intervention delivered to GPs hinged upon increasing
physicians’ awareness of prescribing for the elderly and included three key ele-
ments: i) the initial dissemination of the developed PIMs list, along with a list of
alternative drugs to PIMs; ii) annual reviews of PIMs prevalence data; and (iii) a
series of educational sessions on PIMs via academic detailing and case studies
reviews.We used a pre-post design to analyze the change in quarterly rates of PIMs
in elderly patients aged 365 years in Parma LHU between the study start (pre-
intervention - 2007 fourth quarter (Q4)) and the end of the study (post-intervention
– 2009 Q4), using a neighboring LHU similar in size as a comparator. RESULTS: The
prescription rate of PIMs in the elderly of Parma LHU declined by 19%, from 6.3%
pre-intervention (2007 Q4) to 5.1% post-intervention (2009 Q4), compared to a 12%
reduction in the same time period in the comparator LHU, from 6.8% to 5.9%. The
degree of decline in the rate of PIMs was significantly greater in the LHU of Parma
(Breslow-Day test, p0.004). CONCLUSIONS: A quality intervention program look-
ing at improving knowledge in primary care physicians on prescribing for the el-
derly patients resulted in a substantial reduction of the rate of PIMs. Additional
approaches targeting specific medications or physician characteristics should be
developed to further reduce PIMs rates.
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OBJECTIVES: Pharmaceutical cost containment policies can affect access to med-
icines. The present study compares medicines licensed in the United States (US),
United Kingdom (UK), Australia and New Zealand (NZ), and subsidized by the US
Department of Veterans Affairs National Formulary (VANF), UK National Health
Service (NHS), Australian Pharmaceutical Benefits Scheme (PBS) and NZ’s PHARMAC.
We compare licensed and subsidized medicines in terms of: (i) total numbers of
entities (unique ATC codes), (ii) times since first registration (“age”) of entities, and
(iii) numbers of innovative entities. METHODS: All products listed in a major pre-
scribing reference text in each country were classified by ATC code and their reg-
istration dates recorded. Innovative entities given “fast track” approval by the US
Food and Drug Administration or “breakthrough or substantial improvement” sta-
tus by the Canadian Patented Medicines Review Board were identified. RESULTS:
Of the 918 entities and 64 innovative entities licensed in the US, 505 and 20 respec-
tively were VANF subsidized. In the UK, this was 1020 and 58 (1016 and 58 NHS
subsidized), Australia 879 and 49 (567 and 30 PBS subsidized) andNZ 765 and 39 (503
and 19 PHARMAC subsidized). With the exception of the UK, US licensed entities
were “newer” than elsewhere: US median “age” 6,607 days (VANF 8,203 days, p
0.001), UK 7,319 days (NHS 7,319 days, p 0.903), Australia 7,795 days (PBS 8,065
days, p 0.406), NZ 8,936 days (PHARMAC 10,724 days P0.001). NHS subsidized
entities were “newer” than elsewhere. In the US and NZ, subsidized entities were
significantly “older” than licensed entities. CONCLUSIONS: Different pharmaceu-
tical cost containment policies appear to impact the number and “age” of licensed
and subsidized entities, along with access to innovative entities. The New Zealand
system had the strongest cost containment levers, but subsidised the fewest and
“oldest” entities, and fewest innovative entities.
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OBJECTIVES: The objectives of the survey were to gather information on percep-
tions about biologic agents from payers and providers presently and over the next
18months. Areas of focus included: (1) Perceptions of healthcare reformon biologic
product development, access and reimbursement, and outcomes research require-
ments; (2) Biosimilar pricing; (3) Use of specialty pharmacy providers; (4) Improve-
ments in quality of care, outcomes and costs of target diseases. METHODS: An
online survey was conducted with a select sample of national stakeholders repre-
senting payers and providers during the 4th quarter 2010. RESULTS: Over 80 re-
spondents representing multiple types of payers and providers (ex: health plans,
fed and state government agencies, health systems,) participated in the survey.
Fifty percent (50%) of payers and 30% of providers did not know the percentage of
their organization’s health care spend on biologics, but nearly all knew that their
organization’s health care spend on biologics is increasingly important. Payers and
providers agree (7.7/10 and 7.6/10) that patients will incur more out of pocket ex-
penses for biologics over the next 6-18 months. The 3 greatest areas indicated by
providers and payers for improvement in quality of care and outcomes are: Oncol-
ogy-early stage, RA, and AD. It is perceived that generically interchangeable bio-
similars will be available at an approximate 40% discount. Respondents felt estab-
lishing a value proposition and promoting appropriate use will be key drivers of
importance for biologic agents in the future. Respondents agree that their needs
regarding biologic agents should focus on: outcomes measurement, comparative
effectiveness studies, specialty pharmacy usage, benefit designs, and regulatory
developments through educational initiatives. CONCLUSIONS: Biologics remain a
strong growing area of interest among healthcare stakeholders and monitoring
changes inmarketplace dynamicswith additional research effortswill be key areas
of focus in the future.
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OBJECTIVES: Many countries employ an external reference pricing system where
the price of pharmaceutical is in part governed by the price in selected other coun-
tries thus creating a web of relationships between the prices in different countries.
The objective of this study was to investigate which countries could be considered
the most influential in this network. METHODS: The price referencing pattern
between countries in the European Economic Area was represented as a directed
graphwith each individual country as a node and the existence of price referencing
from one country to another as a directed edge. The importance of each country
was estimated by calculating the eigenvector centrality of each node based on the
adjacency matrix representing the edges of the graph. In an extension, we also
performed an analysis where edges were weighted by the size of the pharmaceu-
tical market in each country. RESULTS:When considering unweighted referencing
between countries, Germany and France were the two most influential countries
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